MA46228A - Inhibiteurs bicycliques fusionnés de l'interaction ménine-mll - Google Patents

Inhibiteurs bicycliques fusionnés de l'interaction ménine-mll

Info

Publication number
MA46228A
MA46228A MA046228A MA46228A MA46228A MA 46228 A MA46228 A MA 46228A MA 046228 A MA046228 A MA 046228A MA 46228 A MA46228 A MA 46228A MA 46228 A MA46228 A MA 46228A
Authority
MA
Morocco
Prior art keywords
menin
mll interaction
bicyclic inhibitors
fusion
fusion bicyclic
Prior art date
Application number
MA046228A
Other languages
English (en)
Inventor
Patrick René Angibaud
Barbara Herkert
Daniel Jason Krosky
Vineet Pande
Aaron Nathaniel Patrick
Olivier Alexis Georges Querolle
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA46228A publication Critical patent/MA46228A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA046228A 2016-09-14 2017-09-13 Inhibiteurs bicycliques fusionnés de l'interaction ménine-mll MA46228A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662394291P 2016-09-14 2016-09-14
EP16192424 2016-10-05
EP17180228 2017-07-07

Publications (1)

Publication Number Publication Date
MA46228A true MA46228A (fr) 2019-07-24

Family

ID=59901513

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046228A MA46228A (fr) 2016-09-14 2017-09-13 Inhibiteurs bicycliques fusionnés de l'interaction ménine-mll

Country Status (13)

Country Link
US (2) US10611778B2 (fr)
EP (1) EP3512858B1 (fr)
JP (1) JP7033141B2 (fr)
KR (1) KR102493364B1 (fr)
CN (1) CN109715634B (fr)
AU (1) AU2017326485B2 (fr)
CA (1) CA3033020A1 (fr)
ES (1) ES2966316T3 (fr)
IL (1) IL265231B (fr)
MA (1) MA46228A (fr)
MX (1) MX389598B (fr)
TW (1) TWI753016B (fr)
WO (1) WO2018050684A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE49687E1 (en) 2014-09-09 2023-10-10 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
TWI703150B (zh) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物
HK1246593A1 (zh) 2015-06-04 2018-09-14 Kura Oncology, Inc. 用於抑制menin蛋白与mll蛋白的相互作用的方法及组合物
PH12018501955B1 (en) 2016-03-16 2024-01-24 Kura Oncology Inc Bridged bicyclic inhibitors of menin-mll and methods of use
PL3429591T3 (pl) 2016-03-16 2023-07-17 Kura Oncology, Inc. Podstawione pochodne tieno[2,3-d]pirymidyny jako inhibitory meniny-mll i metody ich zastosowania
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
EP3512857B1 (fr) 2016-09-14 2021-02-24 Janssen Pharmaceutica NV Inhibiteurs spiro-bicyclique de menin-mll-interaction
CA3033020A1 (fr) 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Inhibiteurs bicycliques fusionnes de l'interaction menine-mll
CN110248946B (zh) 2016-12-15 2023-05-23 詹森药业有限公司 Menin-MLL相互作用的氮杂环庚烷抑制剂
WO2018175746A1 (fr) 2017-03-24 2018-09-27 Kura Oncology, Inc. Méthodes de traitement d'hémopathies malignes et du sarcome d'ewing
WO2018226976A1 (fr) 2017-06-08 2018-12-13 Kura Oncology, Inc. Procédés et compositions d'inhibition de l'interaction de la ménine avec les protéines mll
EP3684361A4 (fr) 2017-09-20 2021-09-08 Kura Oncology, Inc. Inhibiteurs substitués de ménine-mll et méthodes d'utilisation
JP7307729B2 (ja) 2017-12-20 2023-07-12 ヤンセン ファーマシューティカ エヌ．ベー． メニン－ｍｌｌ相互作用のエキソ－アザスピロ阻害剤
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
US11325921B2 (en) 2018-03-30 2022-05-10 Sumitomo Dainippon Pharma Co., Ltd. Optically active crosslinked cyclic secondary amine derivative
ES2991898T3 (es) * 2018-08-08 2024-12-05 Sumitomo Pharma Co Ltd Derivado de piperidina con puente ópticamente activo
KR102779601B1 (ko) * 2018-08-27 2025-03-12 스미토모 파마 가부시키가이샤 광학 활성인 아자비시클로환 유도체
AU2019395201A1 (en) 2018-12-06 2021-05-20 Daiichi Sankyo Company, Limited Cycloalkane-1,3-diamine derivative
TW202525813A (zh) 2019-12-19 2025-07-01 比利時商健生藥品公司 經取代之直鏈螺環接衍生物
CN114516873A (zh) * 2020-11-18 2022-05-20 苏州优理生物医药科技有限公司 一种螺环类化合物、包含其药物组合物及其应用
BR112023015210A2 (pt) 2021-01-29 2023-11-07 Cedilla Therapeutics Inc Inibidores de cdk2 e métodos de uso dos mesmos
CA3215379A1 (fr) 2021-05-08 2022-11-17 Olivier Alexis Georges Querolle Derives spiro substitues
US20240417405A1 (en) 2021-05-08 2024-12-19 Janssen Pharmaceutica Nv Substituted Spiro Derivatives
IL308862A (en) 2021-06-01 2024-01-01 Janssen Pharmaceutica Nv Altered phenyl-1H-pyrrolo[3,2-c]pyridine histories
JP2024521902A (ja) 2021-06-03 2024-06-04 ヤンセン ファーマシューティカ エヌ．ベー． スピロ環状アミンで置換されたピリダジン又は１，２，４－トリアジン
WO2022262796A1 (fr) 2021-06-17 2022-12-22 Janssen Pharmaceutica Nv Sel de bésylate (r)-n-éthyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-méthoxyéthyl)(méthyl)amino)-2-m éthylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide pour le traitement de maladies telles que le cancer
CA3225439A1 (fr) 2021-06-26 2022-12-29 Cedilla Therapeutics, Inc. Inhibiteurs de cdk2 et leurs procedes d'utilisation
CN116903609A (zh) * 2021-11-05 2023-10-20 上海优理惠生医药有限公司 一种化合物、包含其的药物组合物及其应用
CN120529900A (zh) 2022-11-24 2025-08-22 奥莱松基因组股份有限公司 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143749A (en) 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
JP2005527502A (ja) 2002-02-19 2005-09-15 シーブイ・セラピューティクス・インコーポレイテッド Ａ１アデノシン受容体の部分的および全アゴニスト
US20040043959A1 (en) 2002-03-04 2004-03-04 Bloom Laura A. Combination therapies for treating methylthioadenosine phosphorylase deficient cells
JP4660199B2 (ja) * 2002-12-23 2011-03-30 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 置換１−ピペリジン−４−イル−４−アゼチジン−３−イル−ピペラジン誘導体およびそれらのニューロキニン拮抗薬としての使用
US7612078B2 (en) * 2003-03-31 2009-11-03 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-D] pyrimidine compounds
WO2005110410A2 (fr) 2004-05-14 2005-11-24 Abbott Laboratories Inhibiteurs de kinases en tant qu'agents therapeutiques
EP1856128A4 (fr) * 2005-01-19 2009-12-23 Merck & Co Inc Inhibiteurs mitotiques de la kinesine
TWI389913B (zh) * 2008-09-08 2013-03-21 Lg Life Sciences Ltd 并合雜環化合物
JP2011026305A (ja) 2009-06-24 2011-02-10 Daiichi Sankyo Co Ltd イミダゾールカルボニル化合物を含有する医薬組成物
CN102984941B (zh) 2009-09-04 2016-08-17 密执安大学评议会 用于治疗白血病的组合物和方法
EP2646455A4 (fr) 2010-12-03 2014-04-02 Epizyme Inc Modulateurs d'histone méthyltransférase et leurs procédés d'utilisation
US9145438B2 (en) 2010-12-03 2015-09-29 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
WO2014035140A2 (fr) 2012-08-30 2014-03-06 Kainos Medicine, Inc. Composés et compositions pour la modulation de l'activité histone méthyltransférase
CN103664991B (zh) * 2012-09-19 2016-12-28 中国科学院福建物质结构研究所 噻吩[2,3‑d]嘧啶衍生物、其制备方法及其用途
US9745291B2 (en) 2012-12-21 2017-08-29 Epizyme, Inc. PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
CA2894126A1 (fr) 2012-12-21 2014-06-26 Epizyme, Inc. Inhibiteurs de prmt5 et leurs utilisations
DK2935222T3 (en) 2012-12-21 2019-01-07 Epizyme Inc PRMT5 INHIBITORS AND APPLICATIONS THEREOF
WO2014164543A1 (fr) * 2013-03-13 2014-10-09 The Regents Of The University Of Michigan Compositions comprenant des composés thiénopyrimidine et thiénopyridine et procédés d'utilisation associés
US20170119769A1 (en) * 2014-06-10 2017-05-04 The Trustees Of The University Of Pennsylvania Scaffolds for inhibitors of menin-mll interactions
US20170198006A1 (en) 2014-06-25 2017-07-13 Epizyme, Inc. Prmt5 inhibitors and uses thereof
USRE49687E1 (en) * 2014-09-09 2023-10-10 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
WO2016081732A1 (fr) 2014-11-19 2016-05-26 Memorial Sloan-Kettering Cancer Center Thiénopyrimidines et utilisations de celles-ci
MX2017010844A (es) 2015-02-24 2017-12-07 Pfizer Derivados de nucleosidos sustituidos utiles como agentes anticancerosos.
HK1246593A1 (zh) 2015-06-04 2018-09-14 Kura Oncology, Inc. 用於抑制menin蛋白与mll蛋白的相互作用的方法及组合物
TWI703150B (zh) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物
TWI870767B (zh) 2015-08-26 2025-01-21 比利時商健生藥品公司 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物
AU2016378579A1 (en) 2015-12-22 2018-06-14 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-MLL interaction
PL3429591T3 (pl) 2016-03-16 2023-07-17 Kura Oncology, Inc. Podstawione pochodne tieno[2,3-d]pirymidyny jako inhibitory meniny-mll i metody ich zastosowania
PH12018501955B1 (en) 2016-03-16 2024-01-24 Kura Oncology Inc Bridged bicyclic inhibitors of menin-mll and methods of use
JP6991585B2 (ja) 2016-05-02 2022-01-12 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン メニン阻害剤としてのピペリジン
WO2017207387A1 (fr) 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Dérivés d'azétidine spiro condensés en tant qu'inhibiteurs de l'interaction ménine-mml1
WO2017214367A1 (fr) 2016-06-10 2017-12-14 Vitae Pharmaceuticals, Inc. Inhibiteurs de l'interaction ménine-mll
WO2018024602A1 (fr) 2016-08-04 2018-02-08 Bayer Aktiengesellschaft 2,7-diazaspiro [4,4] nonanes
CA3033239A1 (fr) 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Inhibiteurs spiro bicycliques de l'interaction menine-mll
CA3033020A1 (fr) 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Inhibiteurs bicycliques fusionnes de l'interaction menine-mll
EP3512857B1 (fr) 2016-09-14 2021-02-24 Janssen Pharmaceutica NV Inhibiteurs spiro-bicyclique de menin-mll-interaction
AU2017326006B2 (en) 2016-09-16 2021-10-28 Vitae Pharmaceuticals, LLC. Inhibitors of the menin-MLL interaction
WO2018109088A1 (fr) 2016-12-15 2018-06-21 Janssen Pharmaceutica Nv Inhibiteurs d'azépane de l'interaction ménine-mll
WO2018175746A1 (fr) 2017-03-24 2018-09-27 Kura Oncology, Inc. Méthodes de traitement d'hémopathies malignes et du sarcome d'ewing

Also Published As

Publication number Publication date
TW201823249A (zh) 2018-07-01
CN109715634A (zh) 2019-05-03
CN109715634B (zh) 2022-09-27
KR20190046888A (ko) 2019-05-07
US10975100B2 (en) 2021-04-13
CA3033020A1 (fr) 2018-03-22
EP3512858C0 (fr) 2023-11-08
IL265231B (en) 2021-06-30
US10611778B2 (en) 2020-04-07
US20200172556A1 (en) 2020-06-04
MX2019002959A (es) 2019-07-04
KR102493364B1 (ko) 2023-01-27
US20190218230A1 (en) 2019-07-18
AU2017326485B2 (en) 2021-04-22
EP3512858B1 (fr) 2023-11-08
JP7033141B2 (ja) 2022-03-09
TWI753016B (zh) 2022-01-21
ES2966316T3 (es) 2024-04-19
MX389598B (es) 2025-03-11
IL265231A (en) 2019-05-30
BR112019004764A2 (pt) 2019-05-28
AU2017326485A1 (en) 2019-02-21
WO2018050684A1 (fr) 2018-03-22
EP3512858A1 (fr) 2019-07-24
JP2019530745A (ja) 2019-10-24

Similar Documents

Publication Publication Date Title
MA46228A (fr) Inhibiteurs bicycliques fusionnés de l'interaction ménine-mll
IL321844A (en) Menin–MLL interaction inhibitors
DK3512850T3 (da) Inhibitorer af menin-mll-interaktionen
MA47576A (fr) Composés inhibiteurs d'oga bicyclique
MA41551A (fr) Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
EP3518934A4 (fr) Inhibiteurs de l'adénosine 5'-nucléotidase
DK3507291T3 (da) Kondenserede bicykliske sgc-stimulatorer
MA46180A (fr) Analogues de l'amyline
EP3430731A4 (fr) Architecture d'iugw
FI20165061L (fi) Aluksen itsenäinen käyttö
EP3443094A4 (fr) Procédés de réduction de l'expression de c9orf72
EP3514431A4 (fr) Joint fileté
MA51337A (fr) Inhibiteurs spiro exo-aza de l'interaction ménine-mll
EP3481814A4 (fr) Antagonistes de l'intégrine tetrahydronaphthyridinepentanamide
EP3415146A4 (fr) Inhibiteur de l'activation des inflammasomes
DK3432872T3 (da) Eflornithin til anvendelse til behandling af temozolomid tilbagevendende/refraktær anaplastisk astrocytom
EP3484854A4 (fr) Inhibiteurs de l'apoptose
EP3415524A4 (fr) INHIBITEUR D'EXPRESSION DE L'a-SYNUCLÉINE
ITUA20161599A1 (it) Contenitore e procedimento per la realizzazione dello stesso
EP3464384A4 (fr) Construction de protéines de fusion
EP3446828A4 (fr) Centre d'usinage
MA43764A (fr) Inhibiteur monovalent de l'interaction hutnfr1
EP3534888A4 (fr) Modulateurs allostériques hétéroaryle bicycliques substitués de récepteurs nicotiniques de l'acétylcholine
EP3363288A4 (fr) Composition pour la destruction de microalgues ou de sphaerocarpus
EP3331887A4 (fr) Benzodiazépines en tant qu'inhibiteurs de bromodomaines